AR106691A1 - SCALAMINE OPHTHETIC FORMULATIONS - Google Patents

SCALAMINE OPHTHETIC FORMULATIONS

Info

Publication number
AR106691A1
AR106691A1 ARP160103476A ARP160103476A AR106691A1 AR 106691 A1 AR106691 A1 AR 106691A1 AR P160103476 A ARP160103476 A AR P160103476A AR P160103476 A ARP160103476 A AR P160103476A AR 106691 A1 AR106691 A1 AR 106691A1
Authority
AR
Argentina
Prior art keywords
mammal
eye
scalamine
ophthetic
formulations
Prior art date
Application number
ARP160103476A
Other languages
Spanish (es)
Inventor
I Backenroth Samuel
B Taraporewala Irach
Original Assignee
Ohr Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohr Pharmaceutical Inc filed Critical Ohr Pharmaceutical Inc
Publication of AR106691A1 publication Critical patent/AR106691A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición oftálmica caracterizada porque comprende: 0,05 a 0,25% de dilactato de escualamina p/v; 0,5 a 1,5% de ácido bórico p/v y 0,05 a 0,30% de borato de sodio p/v; 0,005 a 0,03% de edetato de sodio p/v; 0,5 a 3,0% de glicerol p/v; 0,20 a 1,0% de propilenglicol p/v; 0,3 a 2,0% de hipromelosa p/v; 0,005 a 0,3% de ácido sórbico p/v; y una cantidad suficiente de agua para inyectables o agua purificada USP. Reivindicación 15: Un método para administrar selectivamente escualamina o una sal aceptable desde el punto de vista farmacéutico de la misma a la esclerótica posterior y a la coroides del(de los) ojo(s) de un mamífero que lo necesita en una cantidad terapéuticamente efectiva para tratar una patología oftálmica, caracterizado el método porque comprende: administrar al(a los) ojo(s) del mamífero la composición de cualquiera de las reivindicaciones 1 a 4.Claim 1: An ophthalmic composition characterized in that it comprises: 0.05 to 0.25% squalamin p / v dilactate; 0.5 to 1.5% boric acid w / v and 0.05 to 0.30% sodium borate w / v; 0.005 to 0.03% sodium edetate w / v; 0.5 to 3.0% glycerol w / v; 0.20 to 1.0% propylene glycol w / v; 0.3 to 2.0% of hypromellose w / v; 0.005 to 0.3% sorbic acid w / v; and a sufficient amount of water for injections or purified water USP. Claim 15: A method of selectively administering squalelamine or a pharmaceutically acceptable salt thereof to the posterior sclera and choroid of the eye (s) of a mammal that needs it in a therapeutically effective amount for treat an ophthalmic pathology, characterized in that the method comprises: administering to the eye (s) of the mammal the composition of any of claims 1 to 4.

ARP160103476A 2015-11-13 2016-11-14 SCALAMINE OPHTHETIC FORMULATIONS AR106691A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562255170P 2015-11-13 2015-11-13

Publications (1)

Publication Number Publication Date
AR106691A1 true AR106691A1 (en) 2018-02-07

Family

ID=58695522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103476A AR106691A1 (en) 2015-11-13 2016-11-14 SCALAMINE OPHTHETIC FORMULATIONS

Country Status (3)

Country Link
AR (1) AR106691A1 (en)
TW (1) TW201720445A (en)
WO (1) WO2017083799A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202034918A (en) * 2018-12-11 2020-10-01 美商卡托斯醫療公司 Methods and compositions of treating an ophthalmic condition
CN114040766A (en) 2019-07-01 2022-02-11 奥库里斯公司 Method for stabilizing the pH of an aqueous composition comprising a drug
JP7470791B2 (en) * 2019-11-21 2024-04-18 サムジン ファーマシューティカル カンパニー，リミテッド Ophthalmic composition for preventing or treating eye diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808628A1 (en) * 2010-08-17 2012-02-23 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
US8530449B2 (en) * 2010-09-09 2013-09-10 Assad S. Sawaya Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye

Also Published As

Publication number Publication date
TW201720445A (en) 2017-06-16
WO2017083799A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
ES2584858T3 (en) Aqueous pharmaceutical compositions containing borate-polyol complexes
CL2017002526A1 (en) Use of formyl 2 peptide receptor agonists to treat inflammatory eye diseases (divisional application No. 2485-2015)
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
CL2019001366A1 (en) Buffered formulations exendin (9-39).
AR082024A1 (en) FORMULATION OF ANTIBODY AGAINST OX40L HUMAN
MX361858B (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
TWI832920B (en) Ophthalmic composition for preventing deterioration of soft contact lenses
SA519410114B1 (en) Topical Cyclosporine-Containing Formulations and Uses Thereof
AR106691A1 (en) SCALAMINE OPHTHETIC FORMULATIONS
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
RU2014125426A (en) PROTECTIVE AGENTS FOR THE CORNEAL AND CONJUNCTIVES OR SUPRESSIVE MEANS FOR KERATO-CONJUNCTIVE INFRINGEMENT
MX2016015211A (en) Topical formulations and uses thereof.
AR111236A1 (en) INTRADIALITICAL USE OF SODIUM TIOSULFATE
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
AR093476A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA
MX2020008360A (en) Crystalline form of bictegravir sodium.
RU2016103098A (en) METHOD FOR PREVENTING AND / OR TREATING CHRONIC INJURY ENCEPHALOPATHY - II
JP2016506931A5 (en)
BR112019005224A2 (en) dosage form for prolonged relief
AU2017261303A1 (en) Ophthalmic compositions
JP6449774B2 (en) Ophthalmic composition for zwitterionic soft contact lenses
MX2013001279A (en) Pharmaceutical composition with a selective enzyme phosphodiesterase inhibitor in an oral gel form.
AR108676A1 (en) PHOSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT

Legal Events

Date Code Title Description
FB Suspension of granting procedure